Sunday, December 26, 2010

Many Older Adults With Diabetes Are Sexually Active But Have Problems

New research from the University of Chicago found that many middle-aged and older Americans with diabetes are sexually active but more likely to experience sexual problems compared with counterparts without diabetes.

Lead author Stacy Lindau, associate professor of obstetrics and gynecology and of medicine at the University of Chicago, and colleagues, wrote about their findings in a paper published 27 August in an online advanced issue of Diabetes Care.


Lindau told the media that:


"Patients and doctors need to know that most middle age and older adults with partners are still sexually active despite their diabetes."


"However, many people with diabetes have sexual problems that are not being addressed," she added.


Senior author Dr Marshall Chin, a professor of medicine at the University of Chicago, said:


"Failure to recognize and address sexual issues among middle-age and older adults with diabetes may impair quality of life and adaptation to the disease."


For their study, Lindau and colleagues examined data from a survey of nearly 2,000 people aged 57 to 85 years, that was performed between July 2005 and March 2006 as part of the National Social Life, Health and Aging Project.


1,993 participants were interviewed at home, completed questionnaires, underwent assessment of medication and gave blood samples so researchers could assess their diabetes status..


From the survey and blood samples, using a diabetes test that measures glycosolated hemoglobin (HbA1c), the researchers were able to categorize the participants according to diabetes status: those with diagnosed diabetes, those with undiagnosed diabetes and those with no sign of diabetes.


The results showed that 47 per cent of the men had diabetes, with about 25 per cent aware and 22 per cent not aware that they had the disease (ie undiagnosed). For the women, the blood test showed that nearly 40 per cent had diabetes, with 20.5 per cent aware of it and 19 per cent unaware of it.


The authors noted that these figures were in line with previous studies of people over 60 and estimates that suggest around 12 million Americans over the age of 60 are living with diabetes (many of whom are unaware of it).


When the researchers examined the sexual activity data, they found that nearly 70 per cent of partnered men with diabetes and 62 per cent of partnered women with diabetes were sexually active: they engaged in sexual activity two or three times a month, which is about the same as older people who do not have diabetes.


" Partnered sexual behaviors did not differ by gender or diabetes status," wrote the authors, but they found that the disease did exact a toll on both the desire and rewards of sexual activity.


While the proportion of men with diagnosed and undiagnosed diabetes who reported experiencing orgasm problems was about the same as the proportion of men without diabetes, erectile difficulty and lack of interest in sex was more common among the men with diagnosed diabetes.

Also, women with undiagnosed diabetes were less likely to talk about sex with their doctor (only 11 per cent said they did), compared to women with diagnosed diabetes (19 per cent), men with undiagnosed diabetes (28 per cent), and men with diagnosed diabetes (47 per cent).

Lindau said that nearly half of women in this age group don't have a partner, and that "women with diabetes are far less likely than women without diabetes to have a partner".


"Those who have partners were more likely than men to avoid sex because of a problem, and were far less likely than men to discuss a sexual problem with their doctors," she explained.


Before this study, not much was known about sexual behavior and problems among people with undiagnosed diabetes.


Lindau explained that perhaps not knowing they have diabetes protects people not yet diagnosed with the disease (probably because it is still in the early stages) from the psychological burden of the stigma that often follows the diagnosis.


"The elevated prevalence of orgasm difficulties in people unaware of their diabetes suggests that these are predominantly physical," she said, adding that:


"The erectile dysfunction and loss of interest among men with a diagnosis may be due in part to the psychological burden of diabetes."


The researchers suggest that diabetes may reduce sexual drive, given that just over 60 per cent of the men without diabetes reported having masturbated in the prior 12 months compared to only 47 per cent of men with both diagnosed and undiagnosed diabetes.


A similar pattern was observed among the women: although fewer overall reported having masturbated in the previous 12 months (22.5 per cent), the proportion of women without diabetes who reported doing so was 29 per cent compared with only 15 per cent of women with diagnosed and undiagnosed diabetes.


Also, as with the men, the women with diagnosed and undiagnosed diabetes reported a higher rate of orgasm difficulties.


Chin said:


"Sexual problems are common in patients with diabetes, and many patients are not discussing these issues with their physicians."


The study was supported by funds from the National Institutes of Health's National Social Life, Health and Aging Project.

Friday, December 17, 2010

Sexual Issues A Major Concern For Cancer Patients Taking New Targeted Drugs


Main Category: Cancer / Oncology
Also Included In: Sexual Health / STDs;  Erectile Dysfunction / Premature Ejaculation
Article Date: 13 Oct 2010


New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found.


At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.


Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking targeted therapies had significantly decreased levels of sexual function and satisfaction.


"The new molecular targeted therapies have been available for 6 or 7 years and researchers and physicians have observed some new side-effects not often reported with chemotherapy such as cutaneous side-effects and gastro-intestinal toxicity. But very few studies have been conducted in the field of sexuality, mainly because patients are not willing to talk with their physicians on this topic," Dr Loriot said.


The researchers surveyed 51 patients (40 men and 11 women) who had been taking molecular targeted therapies for more than three months without progressive disease about changes in their sexual life.


The drugs involved were sunitinib, sorafenib, temsirolimus, everolimus, bevacizumab, tarceva and cetuximab. Men completed the International Index of Erectile Function (IEEF) questionnaire --which includes questions on erectile function, intercourse satisfaction, orgasmic function, sexual desire and overall satisfaction.


Women in the study completed the Female Sexual Function Index (FSFI) questionnaire, which includes questions on desire, arousal, lubrication, orgasm, satisfaction and pain.


The median overall IIEF score for men was 40, just 53% of the maximum score. For women, the median FSFI score was 8.4, just 24% of the maximum.


"The sex lives of the patients in our study had reduced quality and intensity," Dr Loriot said. "We also found that more than half of the patients expressed a wish for a satisfying sexuality, but many of them found it difficult to initiate a discussion on the topic with their doctors."


The impact of treatment on the sexuality of cancer patients is poorly understood, and is generally not considered in clinical trials of treatments, Dr Loriot said.


"Oncologists can address this issue first by assessing this concern more often in clinical trials, and by talking with their patients about it," he said.


He suggested that oncologists could offer patients an assessment for sexual disorders during their treatment course, establish an outpatient clinic to deal with sexual disorders, or, if needed, refer patients to a specialist.


Sexuality is a major concern for cancer patients, as it is for everyone, noted Professor Raphael Catane, Chair of the department of oncology at Sheba Medical Center in Tel Hashomer, Israel. "The disease itself, and frequently its therapy, may have a major detrimental effect on the patient's sex life. It is hoped that the new biological/targeted treatments would be less injurious to the sexual life of cancer patients. "


"The study by this French group has taken an important step toward understanding the effect of biological/targeted treatments on sexuality," Prof Catane said. "They meticulously reviewed the sexual function of their patients receiving biological agents. The results show a diminished sexual drive and pleasure, but the degree and the duration, and how it compares to the standard/conventional therapy, is not yet known. This study can be a basis for further investigation of this very important aspect of cancer therapy."


Source:
Vanessa Pavinato
European Society for Medical Oncology




Thursday, December 16, 2010

Understanding The Effects Of Sildenafil Treatment On Erection Maintenance And Erection Hardness



UroToday.com - In our recent article published in the Journal of Sexual Medicine, we used statistical modeling to make the first-reported estimate of the extent to which treatment of erectile dysfunction (ED) affects erection maintenance directly versus indirectly via erection hardness. Because erection maintenance (along with erection hardness) is a physiologic requirement for satisfactory sexual performance, our aim was to guide treatment goals toward optimizing erection maintenance and therefore achieving successful sexual intercourse.
Our statistical models (longitudinal modeling, mapping, and mediation modeling) explored the interrelationships among effective treatment of ED, erection hardness, and erection maintenance in men with ED, using patient reported outcomes from a multinational randomized, double-blind placebo-controlled trial of fixed-dose sildenafil (100 or 50 mg, 8 wk) with open-label extension of flexible-dose sildenafil (50 and 100 mg, 4 wk). Longitudinal models obtain measurements on the same individuals repeatedly through time to estimate within-individual changes in the response variable and to relate these changes to inter-individual differences in selected covariates (eg, treatment group). Mapping enables interpretation of an outcome of interest (eg, erection maintenance) in terms of a known outcome (eg, erection hardness). A mediation model seeks to identify and explain the mechanism that underlies an observed relationship between an independent variable (eg, treatment) and a dependent variable (eg, erection maintenance) via the inclusion of a mediator variable (eg, erection hardness). The mediator variable clarifies the nature of the interrelationships among variables. In our models, measures of interest included the Erection Hardness Score (EHS) to gauge erection hardness and the two maintenance items (items 4 and 5) on the International Index of Erectile Function (IIEF) to gauge erection maintenance (see Tables). Separate models were implemented for each of the two maintenance items.
Maintenance: International Index of Erectile Function
Item 4: During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?
Item 5: During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?
Hardness: Erection Hardness Score
"How would you rate the hardness of your erection?"
0: Penis does not enlarge.
1: Penis is larger but not hard.
2: Penis is hard but not hard enough for penetration.
3: Penis is hard enough for penetration but not completely hard.
4: Penis is completely hard and fully rigid.
Longitudinal mean differences on the outcomes for sildenafil 100 and 50 mg vs. placebo (in the double-blind phase) were high (P<0.0001 for each), with large standardized effect sizes (>0.8).
For the mapping of erection hardness (EHS) onto maintenance (items 4 and 5 on IIEF), which included all available data and combined all treatment groups, correlations between EHS and IIEF items 4 and 5 ranged from 0.54 to 0.73 - and the mapping of the relationship between EHS and IIEF items 4 or 5 can be approximated as linear.
In our mediation model, which used data in the double-blind portion and pooled sildenafil into one active treatment, erection hardness was defined by the EHS and erection maintenance was defined by item 4 and, separately, by item 5 on the IIEF. The indirect effect of sildenafil treatment (vs. placebo) via erection hardness accounted for 55.4% (standard error [SE]=7.9%) and 43.1% (SE=6.8%) of the total effect of sildenafil treatment on IIEF maintenance item 4 and item 5, respectively, whereas the direct effect of treatment on IIEF items 4 and 5 was 44.6% (SE=7.9%) and 56.9% (SE=6.8%), respectively (P<0.0001 for each).
Sildenafil treatment significantly improved erection maintenance, a physiologic requirement for satisfactory sexual performance. According to our model, only approximately half of the effect of sildenafil on erection maintenance was estimated to be driven through direct effects. Rather, the effect of sildenafil on erection maintenance seems to be substantially driven by erection hardness. Therefore, achievement of optimal initial erection hardness appears to be an important treatment goal for enhancing erection maintenance and achieving successful ED treatment.
Written by Hubert IM Claes, MD, PhD,* Irwin Goldstein, MD,† Stanley E. Althof, PhD,‡ Michael M. Berner, MD,§ Joseph C Cappelleri, PhD, MPH,** Andrew G Bushmakin, MS,** Tara Symonds, PhD,†† and Gabriel Schnetzler, MD‡‡ as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations, etc., of their research by referencing the published abstract.
Department of Urology, University Clinics Gasthuisberg, Leuven, Belgium; †Sexual Medicine, Alvarado Hospital and Department of Surgery, University of California at San Diego, CA, USA; ‡ Miller School of Medicine, University of Miami, Miami, FL,USA; §University Hospital Medical Center, Freiburg, Germany; **Pfizer Inc, Global Research & Development, New London, CT, USA; ††Pfizer Ltd Outcomes Research, Sandwich, UK; ‡‡Pfizer International Operations, Paris, France
Acknowledgments:
The study on which this report is based was sponsored by Pfizer Inc. Editorial support was provided by Deborah M. Campoli-Richards, BSPHA, RPh, of Complete Healthcare Communications, Inc., and was funded by Pfizer Inc.
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2010 - UroToday
Bookmark and Share
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
All opinions are moderated before being added.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:




View the original article here